Soligenix, Inc. (NASDAQ:SNGX – Get Free Report) saw a large decrease in short interest in October. As of October 31st, there was short interest totalling 47,100 shares, a decrease of 64.9% from the October 15th total of 134,300 shares. Currently, 2.1% of the company’s shares are sold short. Based on an average daily trading volume, of 135,700 shares, the days-to-cover ratio is currently 0.3 days.
Hedge Funds Weigh In On Soligenix
Hedge funds have recently modified their holdings of the business. Armistice Capital LLC purchased a new position in shares of Soligenix during the 2nd quarter worth $206,000. Stephens Inc. AR purchased a new position in shares of Soligenix during the 3rd quarter worth $184,000. Finally, OLD National Bancorp IN purchased a new position in shares of Soligenix during the 2nd quarter worth $26,000. 3.60% of the stock is currently owned by hedge funds and other institutional investors.
Soligenix Stock Down 3.8 %
NASDAQ:SNGX traded down $0.14 during trading hours on Friday, hitting $3.54. The company had a trading volume of 16,193 shares, compared to its average volume of 840,603. The company has a 50-day moving average of $3.76 and a 200 day moving average of $4.36. Soligenix has a 1 year low of $1.83 and a 1 year high of $32.00.
About Soligenix
Soligenix, Inc, a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX302, an IDR technology which is in Phase IIa study to treat mil-to-moderate Psoriasis; and SGX945 and IDR technology that is in Phase IIa protocol for the treatment of Aphthous Ulcers in Behçet's Disease.
Featured Stories
- Five stocks we like better than Soligenix
- What Are Dividend Champions? How to Invest in the Champions
- How Whitestone REIT is Transforming Sunbelt Retail Growth
- What is a Death Cross in Stocks?
- Top-Performing Non-Leveraged ETFs This Year
- With Risk Tolerance, One Size Does Not Fit All
- Rivian’s Wild Ride: Is the Dip a Buying Opportunity?
Receive News & Ratings for Soligenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Soligenix and related companies with MarketBeat.com's FREE daily email newsletter.
